Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Private-label Midol

This article was originally published in The Tan Sheet

Executive Summary

Private-label Midol: ANDAs for ibuprofen 200 mg capsules may be approved by FDA because the drug "was not withdrawn from sale for reasons of safety or effectiveness," the agency announced in a recent Federal Register notice. Responding to a June 27 citizen petition from Pharmaceutical Formulations of Edison, N.J. (formerly Private Formulations) regarding the status of the ibuprofen formulation, FDA determined that "never marketing an approved drug product is equivalent to withdrawing the drug from sale." Sterling Winthrop received approval for Midol 200 mg capsules on Sept. 7, 1987, but neither Sterling nor Bayer, which acquired Sterling's North American OTC business in late 1994, has marketed the product in that dosage strength...

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS086404

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel